Krebs Biochemicals & Industries Limited (NSE:KREBSBIO)
India
· Delayed Price · Currency is INR 76.45
+1.85 (2.48%)
May 29, 2025, 3:31 PM IST
NSE:KREBSBIO Revenue
In the fiscal year ending March 31, 2025, Krebs Biochemicals & Industries had annual revenue of 433.12M INR, down -14.10%. Krebs Biochemicals & Industries had revenue of 61.01M in the quarter ending March 31, 2025, a decrease of -49.05%.
Revenue
433.12M
Revenue Growth
-14.10%
P/S Ratio
3.88
Revenue / Employee
2.27M
Employees
191
Market Cap
1.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 433.12M | -71.10M | -14.10% |
| Mar 31, 2024 | 504.22M | -17.13M | -3.29% |
| Mar 31, 2023 | 521.34M | -75.69M | -12.68% |
| Mar 31, 2022 | 597.03M | 70.20M | 13.32% |
| Mar 31, 2021 | 526.84M | 202.88M | 62.63% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 271.45B |
| Apollo Hospitals Enterprise | 211.46B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 127.57B |
Krebs Biochemicals & Industries News
- 3 months ago - Krebs Biochemicals & Industries halts production following order from Andhra Pradesh Pollution Control Board - Business Upturn